Jane Street Group, LLC Rain Therapeutics Inc. Transaction History

Jane Street Group, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.22 $37,978 - $55,158	45,212 New	45,212 $54,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $57,672 - $525,406	52,911 Added 138.33%	91,162 $109,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $170,520 - $273,666	21,946 Added 134.6%	38,251 $334,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $8.48 $90,003 - $138,266	16,305 New	16,305 $130,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.